NAFLD as the metabolic hallmark of obesity
- 10.11.2022
- IM - REVIEW
Erschienen in:
- Verfasst von
- Alba Rojano
- Elena Sena
- Ramiro Manzano-Nuñez
- Juan M. Pericàs
- Andreea Ciudin
- Erschienen in
- Internal and Emergency Medicine | Ausgabe 1/2023
Abstract
Non-alcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide, associated with a high risk of progression to NASH, liver cirrhosis and hepatocarcinoma. Its prevalence is closely related to obesity (understood as adipose-based disease and insulin resistance), which makes that at present NAFLD can be considered a metabolic dysfunction hallmark, regardless of the body mass index. Despite being such a prevalent condition, with such severe consequences, at present there are no reliable biomarkers for its diagnosis or specific treatment. Significant and sustained weight loss, as well as some antidiabetic treatments, has shown promising results for NAFLD but data needs confirmation in larger clinical trials and longer follow-up. Efforts should be made for a better and more accurate baseline diagnosis (including large-scale genetics), identification of patients at higher risk for progression to NASH as well as adequate treatment, to allow us to offer a personalized approach in NAFLD in the context of precision medicine.
Anzeige
- Titel
- NAFLD as the metabolic hallmark of obesity
- Verfasst von
-
Alba Rojano
Elena Sena
Ramiro Manzano-Nuñez
Juan M. Pericàs
Andreea Ciudin
- Publikationsdatum
- 10.11.2022
- Verlag
- Springer International Publishing
- Erschienen in
-
Internal and Emergency Medicine / Ausgabe 1/2023
Print ISSN: 1828-0447
Elektronische ISSN: 1970-9366 - DOI
- https://doi.org/10.1007/s11739-022-03139-x
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.
